All In Biotech

Drug Trial Radar · NCT04168190

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults.

Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Dec 6, 2019

Primary completion

Jul 12, 2021

Study completion Jul 12, 2021

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistically significantly greater following vaccination with V116 than those following vaccination with Pneumovax™23.

Conditions

  • Pneumonia, Pneumococcal

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • Pneumovax™23Biological

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)Time frame: Up to 5 days post-vaccination
  2. Phase 1: Percentage of Participants With a Solicited Systemic AETime frame: Up to 5 days post-vaccination
  3. Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to Day 195
  4. Phase 2: Percentage of Participants With a Solicited Injection-site AETime frame: Up to 5 days post-vaccination
  5. Phase 2: Percentage of Participants With a Solicited Systemic AETime frame: Up to 5 days post-vaccination
  6. Phase 2: Percentage of Participants With Vaccine-related SAEsTime frame: Up to Day 293
  7. Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23Time frame: 30 days post vaccination
  8. Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116Time frame: 30 days post vaccination

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Simon Williamson Clinic ( Site 0004)

    Birmingham, Alabama

  • Central Arizona Medical Associates ( Site 0003)

    Mesa, Arizona

  • Clinical Research of South Florida ( Site 0008)

    Coral Gables, Florida

  • Indago Research & Health Center, Inc ( Site 0011)

    Hialeah, Florida

  • Research Centers of America, LLC ( Site 0001)

    Hollywood, Florida

  • QPS Miami Research Associates ( Site 0016)

    Miami, Florida

  • L&C Professional Medical Research Institute ( Site 0009)

    Miami, Florida

  • Advanced Medical Research Institute ( Site 0010)

    Miami, Florida

  • Optimal Research ( Site 0006)

    Peoria, Illinois

  • Benchmark Research ( Site 0012)

    Metairie, Louisiana

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0018)

    Troy, Michigan

  • Meridian Clinical Research, LLC ( Site 0024)

    Norfolk, Nebraska

  • Wake Research Clinical Research Center of Nevada, LLC ( Site 0014)

    Las Vegas, Nevada

  • Meridian Clinical Research, LLC ( Site 0025)

    Endwell, New York

  • Rochester Clinical Research, Inc. ( Site 0002)

    Rochester, New York

  • PriMED Clinical Research ( Site 0021)

    Dayton, Ohio

  • Advanced Medical Research ( Site 0017)

    Maumee, Ohio

  • Kaiser Permanente Center for Health Research ( Site 0015)

    Portland, Oregon

  • Diagnostics Research Group ( Site 0013)

    San Antonio, Texas

  • Advanced Clinical Research ( Site 0022)

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.